NO932326L - Hydroksaminsyrederivater - Google Patents

Hydroksaminsyrederivater

Info

Publication number
NO932326L
NO932326L NO932326A NO932326A NO932326L NO 932326 L NO932326 L NO 932326L NO 932326 A NO932326 A NO 932326A NO 932326 A NO932326 A NO 932326A NO 932326 L NO932326 L NO 932326L
Authority
NO
Norway
Prior art keywords
alkyl
atom
hydrogen
amino acid
carbamoyl
Prior art date
Application number
NO932326A
Other languages
English (en)
Other versions
NO932326D0 (no
Inventor
Michale John Broadhurst
Paul Anthony Brown
Geoffrey Lawton
William Henry Johnson
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929213473A external-priority patent/GB9213473D0/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO932326D0 publication Critical patent/NO932326D0/no
Publication of NO932326L publication Critical patent/NO932326L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Oppfinnelsen tilveiebringer hydroksaminsyrederivater med formel (I) hvor R1 betyr 1-7 C-alkyl; R2 betyr hydrogen, 1-6 C- alkyl eller en gruppe med formelen -(CH2)n-aryl eller -(CH2)n-Het, hvori n betyr 1-4, og Het betyr en 5- eller 6-leddet N-heterosyklisk ring som (a) er forbundet via N-atomet, (b) eventuelt inneholder N, O og/eller s som ytterligere heteroatom(er) i en stilling eller stillinger som ikke er tilstøtende til det forbindende N-atom, (c) er substituert med okso på ett eller begge C-atomer i nabostilling til det forbindende N-atom, og (d) er eventuelt benz-kon- densert eller eventuelt substituert på ett eller flere andre karbonatomer med 1-6 C-alkyl eller okso og/eller på et hvilket som helst ytterligere N atom(er) med 1-6 C-alkyl; R3 betyr den karakteriserende gruppe av en naturlig eller ikke-naturlig a-aminosyre, i hvilken enhver tilstedeværende funksjonell gruppe kan være beskyttet; med det forbehold at R3 ikke betyr hydrogen; R4 betyr karboksyl, (1-6 C alkoksy)karbonyl, karbamoyl eller (1-6 C alkyl)karbamoyl; R5 betyr den karakteriserende gruppe i en naturlig forekommende a- aminosyre, hvori enhver tilstedeværende funksjonell gruppe kan være beskyttet; og R6 betyr hydrogen; eller R4, R5 og R6 betyr hver for seg hydrogen eller en 1-6 C-alkyl, og deres farmasøytisk aksepterbare salter, som er matrise-metalloproteinase-inhibitorer anven- delige for kontrollen eller forhindring av degenere- tive leddsykdommer slik som rheumatoid artrititt og osteoartrititt eller for behandling av invasive tumorer, arterosklerose eller multiple sklerose. De kan fremstilles i henhold til generelt kjente metoder ved å avblokkere en tilsvarende ny benzyloksyaminofor- bindelse eller hydroksyamidere en tilsvarende ny aminosyre eller et aktivert derivat derav.
NO932326A 1992-06-25 1993-06-24 Hydroksaminsyrederivater NO932326L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929213473A GB9213473D0 (en) 1992-06-25 1992-06-25 Hydroxamic acid derivatives
GB939307081A GB9307081D0 (en) 1992-06-25 1993-04-05 Hydroxamic acid derivatives

Publications (2)

Publication Number Publication Date
NO932326D0 NO932326D0 (no) 1993-06-24
NO932326L true NO932326L (no) 1993-12-27

Family

ID=26301123

Family Applications (1)

Application Number Title Priority Date Filing Date
NO932326A NO932326L (no) 1992-06-25 1993-06-24 Hydroksaminsyrederivater

Country Status (19)

Country Link
EP (1) EP0575844B1 (no)
JP (1) JP2594014B2 (no)
CN (1) CN1054599C (no)
AT (1) ATE162514T1 (no)
AU (1) AU666727B2 (no)
BG (1) BG97895A (no)
CA (1) CA2098166A1 (no)
CZ (1) CZ118393A3 (no)
DE (1) DE69316456T2 (no)
DK (1) DK0575844T3 (no)
ES (1) ES2112929T3 (no)
FI (1) FI932950A7 (no)
GR (1) GR3026623T3 (no)
HU (1) HU9301773D0 (no)
IL (1) IL106059A0 (no)
IS (1) IS4041A (no)
NO (1) NO932326L (no)
NZ (1) NZ247926A (no)
SK (1) SK64993A3 (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892112A (en) * 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
GB9401129D0 (en) * 1994-01-21 1994-03-16 British Bio Technology Hydroxamic acid derivatives as metalloproteinase inhibitors
JP3827324B2 (ja) * 1994-01-22 2006-09-27 ブリテッシュ バイオテック ファーマシューティカルズ リミテッド 金属タンパク質分解酵素阻害剤
GB2300188B (en) * 1994-01-22 1998-07-01 British Biotech Pharm Metalloproteinase inhibitors
US5514716A (en) * 1994-02-25 1996-05-07 Sterling Winthrop, Inc. Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
GB9501737D0 (en) * 1994-04-25 1995-03-22 Hoffmann La Roche Hydroxamic acid derivatives
WO1995032944A1 (en) * 1994-05-28 1995-12-07 British Biotech Pharmaceuticals Limited Succinyl hydroxamic acid, n-formyl-n-hydroxy amino carboxylic acid and succinic acid amide derivatives as metalloprotease inhibitors
GB9411088D0 (en) * 1994-06-03 1994-07-27 Hoffmann La Roche Hydroxylamine derivatives
GB9411598D0 (en) * 1994-06-09 1994-08-03 Hoffmann La Roche Hydroxamic acid derivatives
US5831004A (en) 1994-10-27 1998-11-03 Affymax Technologies N.V. Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use
US5840698A (en) * 1994-10-27 1998-11-24 Affymax Technologies N.V. Inhibitors of collagenase-1 and stormelysin-I metalloproteases, pharmaceutical compositions comprising same and methods of their use
GB9423914D0 (en) * 1994-11-26 1995-01-11 British Biotech Pharm Polyether derivatives as metalloproteinase inhibitors
US5639746A (en) * 1994-12-29 1997-06-17 The Procter & Gamble Company Hydroxamic acid-containing inhibitors of matrix metalloproteases
US5672598A (en) * 1995-03-21 1997-09-30 The Procter & Gamble Company Lactam-containing hydroxamic acids
US5691381A (en) * 1995-04-18 1997-11-25 The Dupont Merck Pharmaceutical Company Hydroxamic and carbocyclic acids as metalloprotease inhibitors
GB9507799D0 (en) * 1995-04-18 1995-05-31 British Biotech Pharm Metalloproteinase inhibitors
US5703092A (en) * 1995-04-18 1997-12-30 The Dupont Merck Pharmaceutical Company Hydroxamic acid compounds as metalloprotease and TNF inhibitors
WO1996033733A1 (en) * 1995-04-25 1996-10-31 Fuji Yakuhin Kogyo Kabushiki Kaisha Novel remedy for skin deficiencies
DE69632821T2 (de) * 1995-04-25 2005-08-25 Daiichi Fine Chemical Co., Ltd., Takaoka In wasser hochlöslicher metalloproteinase-inhibitor
AU706064B2 (en) * 1995-05-10 1999-06-10 Darwin Discovery Limited Peptide compounds which inhibit metalloproteinase and TNF liberation, and their therapeutic use
US5677282A (en) * 1995-06-07 1997-10-14 Proscript, Inc. Amino acid amides of 1,3,4-thiadiazoles as matrix metalloproteinase
US5917090A (en) * 1995-06-30 1999-06-29 British Biotech Pharmaceuticals Ltd. Matrix metalloproteinase inhibitors
JP2000500761A (ja) 1995-11-23 2000-01-25 ブリティッシュ バイオテック ファーマシューティカルズ リミテッド 金属タンパク質分解酵素阻害剤
EP0923561B1 (en) * 1996-08-28 2002-10-23 The Procter & Gamble Company Heterocyclic metalloprotease inhibitors
IL128661A (en) * 1996-08-28 2001-10-31 Procter & Gamble Teleprotease inhibitors 1, 3 - diethocycles and pharmaceutical preparations containing them
WO1998008850A1 (en) * 1996-08-28 1998-03-05 The Procter & Gamble Company Spirocyclic metalloprotease inhibitors
WO1998008827A1 (en) * 1996-08-28 1998-03-05 The Procter & Gamble Company Heterocyclic metalloprotease inhibitors
ATE226590T1 (de) * 1996-08-28 2002-11-15 Procter & Gamble Phosphinsäureamide als matrix metalloprotease inhibitoren
US6462023B1 (en) 1996-09-10 2002-10-08 British Biotech Pharmaceuticals, Ltd. Cytostatic agents
NZ333923A (en) 1996-09-10 2000-11-24 British Biotech Pharm Cytostatic hydroxamic acid derivatives for inhibiting proliferation of tumour cells
US5952320A (en) * 1997-01-07 1999-09-14 Abbott Laboratories Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
ZA9818B (en) * 1997-01-07 1998-07-02 Abbott Lab C-terminal ketone inhibitors of matrix metalloproteinases and tnf alpha secretion
US5985911A (en) * 1997-01-07 1999-11-16 Abbott Laboratories C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion
JP2001513484A (ja) 1997-07-31 2001-09-04 ザ プロクター アンド ギャンブル カンパニー 非環式メタロプロテアーゼ阻害剤
US6329418B1 (en) 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
CN1349498A (zh) 1999-03-03 2002-05-15 宝洁公司 含有链烯基和炔基的金属蛋白酶抑制剂
JP2001055327A (ja) * 1999-06-11 2001-02-27 Fuji Chemical Industries Ltd 新規なヒドロキサム酸誘導体を含む医薬
US6696456B1 (en) 1999-10-14 2004-02-24 The Procter & Gamble Company Beta disubstituted metalloprotease inhibitors
CA2401728A1 (en) 2000-03-21 2001-09-27 The Procter & Gamble Company Difluorobutyric acid metalloprotease inhibitors
RU2245876C2 (ru) 2000-03-21 2005-02-10 Дзе Проктер Энд Гэмбл Компани Производные сульфонамидов и фармацевтическая композиция на их основе
GB0421308D0 (en) * 2004-09-24 2004-10-27 Amersham Plc Enzyme inhibitor imaging agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743587A (en) * 1985-09-10 1988-05-10 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
US4771038A (en) * 1986-01-21 1988-09-13 Ici Americas Inc. Hydroxamic acids
GB8601368D0 (en) * 1986-01-21 1986-02-26 Ici America Inc Hydroxamic acids
DK77487A (da) * 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
GB8630721D0 (en) * 1986-12-23 1987-02-04 Unilever Plc Cosmetic compositions
US5189178A (en) * 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
CA2073510A1 (en) * 1990-12-03 1992-06-04 Celltech Therapeutics Limited Peptidyl derivatives

Also Published As

Publication number Publication date
EP0575844B1 (en) 1998-01-21
CN1082027A (zh) 1994-02-16
IS4041A (is) 1993-12-26
EP0575844A3 (no) 1994-03-09
ATE162514T1 (de) 1998-02-15
ES2112929T3 (es) 1998-04-16
FI932950A0 (fi) 1993-06-24
CN1054599C (zh) 2000-07-19
DE69316456T2 (de) 1998-07-09
HU9301773D0 (en) 1993-09-28
NO932326D0 (no) 1993-06-24
SK64993A3 (en) 1994-01-12
CA2098166A1 (en) 1993-12-26
FI932950A7 (fi) 1993-12-26
DE69316456D1 (de) 1998-02-26
IL106059A0 (en) 1993-10-20
JP2594014B2 (ja) 1997-03-26
JPH0687813A (ja) 1994-03-29
CZ118393A3 (en) 1994-02-16
NZ247926A (en) 1995-10-26
AU3993193A (en) 1994-01-06
GR3026623T3 (en) 1998-07-31
EP0575844A2 (en) 1993-12-29
AU666727B2 (en) 1996-02-22
BG97895A (en) 1994-06-30
DK0575844T3 (da) 1998-09-14

Similar Documents

Publication Publication Date Title
FI932950A0 (fi) Hydroxiaminsyra derivat
NO932117L (no) Hydroksaminsyrederivater
TW375609B (en) 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
DK0606024T3 (da) Erythromycinderivater, en fremgangsmåde til deres fremstilling samt deres anvendelse som lægemidler
MY110517A (en) Indoline derivatives carrying an amide functional group their preparation and the pharmaceutical compositions in which they are present.
DK34793D0 (da) Vandoploeseligt, farmaceutisk acceptabelt salt af et monoacylderivat af rapamycin, fremgangsmaade til dets fremstilling og injicerbart, farmaceutisk praeparat indeholdende det
RU93005332A (ru) Производные 4,1-бензоксазепина, фармацевтическая композиция, способ лечения
DE122008000051I1 (de) 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel
NO813359L (no) Fremgangsmaate for fremstilling av 1,2,3,4-tetrahydro-isokinolin-3-karboksylsyre-derivater
DK0605228T3 (da) Thiazolidindionderivater, deres fremstilling og anvendelse
NO954975L (no) Aromatisk substituerte w-amino-alkansyreamider og alkansyrediamider
AU8147891A (en) N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present
KR880007461A (ko) 헤테로 사이클-치환 디포스포네이트화합물 및 이의 약제학적 조성물
DK270289A (da) Oligopeptider med cycliske, prolin-analoge aminosyrer og farmaceutisk acceptable salte deraf samt deres anvendelse
EP0309424A3 (en) New amidino derivatives
NO944121L (no) Epoksyravsyrederivater
ATE356816T1 (de) Trizyklische keto amid derivative als farnesyl protein transferase inhibitoren
DK23883A (da) Fremgangsmaade til fremstilling af amidderivater
HUP9900748A1 (hu) Pirrolidinszármazékok alkalmazása alkoholizmus kezelésére alkalmas gyógyszerkészítmények előállítására
SE8306764L (sv) Nya etendiamin- och guanidin-derivat
NO933478L (no) 6-heterocyklisk-4-amino-1,2,2a,3,4,5-heksahydrobenz(CD)indoler for behandling av reisesyke og oppkast
MY134743A (en) Derivatives of hydroxyamino-succinic acid
NO993124L (no) Nye erytromycinderivater, fremgangsmåte for fremstilling av disse samt deres anvendelse som medisiner
AU8147691A (en) 6-alkylpyridazine derivatives, method of preparation and pharmaceutical compositions in which they are present
DEFORMYIASE It is the aim of the present invention to prepare new inhibi-tors of peptide deformylase that are obtainable synthetically